BioVentrix Additions

AlixPartners Forecasts: Household Products Could Cost U.S. Manufacturers and Consumers 15% More This Year Due to Resin Shortage

While companies can’t control the market forces at play, they can take action to mitigate the risk and impact of supply chain disruption.

How To Control a Radio Frequency (RF) Process

The radio frequency welding and manufacturing process uses electromagnetic energy and pressure to fuse and permanently bond vinyl, thermoplastic, and coated materials to produce a specific product - all according to customer requirements. Using this RF sealing process, a distinct, one-piece perpetual bond is formulated that is both solid and resistant to ripping or tearing. But how is this process controlled, and with what specific tools? Read on.

Cartessa Aesthetics’ Innovative Multi-Modality Treatment Leads Demand for Non-Invasive Body Procedures

PHYSIQ is a novel, dual-modality system that offers deep heat to target tissue and electrical muscle stimulation (EMS) to re-educate muscle – all from one device and in one session.

BioVentrix, Inc., a pioneer of technologies and procedures for the less invasive treatment of heart failure (HF), today announced two significant additions to its executive team.

Thasee Pillay, MBChB has been named Chief Medical Officer for Europe and William Abbott has been named Chief Financial Officer.

“The appointments of Dr. Pillay and Mr. Abbott to key roles in our leadership team mark a significant milestone in BioVentrix’s development as we continue to scale the Company,” says Kenneth Miller, President and Chief Executive Officer of BioVentrix, Inc. “Dr. Pillay will lead our clinical development & training efforts in Europe. He has held appointments in the UK, US and India as a cardiac surgeon with special interest in advanced surgical techniques. He is an expert in beating heart CABG, mini access AVR, sutureless AVR and heart and lung transplantation.”

“In his capacity as Chief Financial Officer, Mr. Abbott will be responsible for all operational, transactional and strategic financial initiatives within the company. He comes to us well prepared.  He has been a CFO for 15 years for companies such as Hancock Jaffe, Apollo Medical, and Cardiogenesis, and prior to that served in various VP of Finance/Accounting roles for another 15 years.  Recently, he successfully took a company through an IPO and listing on NASDAQ; and has successfully led several secondary public offerings.”

BioVentrix developed The Revivent TCTM TransCatheter Ventricular Enhancement System to treat patients suffering from ischemic heart failure due to a previous heart attack.  Based on European data, the Revivent TC therapy offers patients with abnormally dilated hearts the benefits of ventricular volume reduction (30%) with increased ejection fraction (17%) and improved quality of life (37%) via Less Invasive Ventricular EnhancementTM (LIVETM).

Watch Linda Marshall’s Experience with The Revivent TC Therapy

BioVentrix is a privately held medical device company headquartered in San Ramon, CA, USA. Our mission is to improve and expand the treatment available for congestive heart failure (CHF) caused by ischemic cardiomyopathy, through the development of less invasive, catheter-based approaches.

Less Invasive Ventricular Enhancement™ or LIVE™ is a revolutionary procedure which offers a new treatment option for patients suffering from ischemic cardiomyopathy. The Revivent TC™ TransCatheter Ventricular Enhancement System is a safer and less invasive alternative compared to a ventricular assist device (VAD) or a heart transplant. It was developed for the purpose of excluding discrete left ventricular scar, thereby reconfiguring abnormal cardiac geometry that leads to dysfunction. Our unique system provides a new solution for multidisciplinary heart teams and their patients by its proven clinical improvements.

spot_img

DON'T MISS

Mediclinic Appoints 2 New Independent Non-Executive Directors

Natalia Barsegiyan and Zarina Bassa will bring significant and diverse skills and experience, complementing those of existing Board members. I am confident they will both be great additions to our Board of Directors.”

Asensus Surgical Appoints Two New Board Members

Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced the expansion of its Board of Directors, appointing...

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.